|
業務類別
|
Biotechnology |
|
業務概覽
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
| 公司地址
| 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612 |
| 電話號碼
| +1 813 875-6600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tuhurabio.com |
| 員工數量
| 19 |
| Mr. Daniel Dearborn |
Chief Financial Officer and Principal Accounting Officer |
美元 339.10K |
31/03/2025 |
| Dr. James A. Bianco,M.D. |
President, Chief Executive Officer and Director |
美元 463.73K |
31/03/2025 |
|
|
| Dr. Alan List, M.D. |
Independent Director |
31/03/2025 |
| Dr. James S.J. Manuso, M.B.A.,PhD |
Independent Director |
31/03/2025 |
| Mr. George K. Ng |
Independent Director |
31/03/2025 |
| Mr. Robert E. Hoffman, C.P.A. |
Director |
31/03/2025 |
| Dr. Craig Tendler, M.D. |
Director |
12/03/2025 |
| Dr. James A. Bianco,M.D. |
President, Chief Executive Officer and Director |
31/03/2025 |
|
|
|
|
